Moreover, FXR signaling mediates reduction in IL-17 production and inflammation in IBD models [222], antagonizes macrophage-dependent licensing of effector T cells in PSC, and shows promising results in treating cholestatic liver disease [149,150]. The gene discussed is IL17A; the disease is inflammatory bowel disease.